Kewaunee Scientific stock reports weaker fiscal Q1 results

Published on 10/05/2026 at 11:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kewaunee Scientific stock closed at USD 34.16 on October 2, 2026, after fiscal Q1 sales fell 6.7 percent year over year. Backlog rose to USD 169.0 million.

KEQU, US4928541048, Illustration mit AI erstellt.

Kewaunee Scientific (ISIN US4928541048) closed at USD 34.16 on Nasdaq on October 2, 2026, up 0.74 percent from the prior close. The company’s fiscal Q1 2027 results released on September 9 showed lower sales and earnings, while backlog increased to USD 169.0 million.

Sales fell in fiscal Q1

According to PR Newswire on September 9, 2026, sales for the quarter ended July 31, 2026, were USD 66.32 million, down 6.7 percent from USD 71.10 million in the prior-year quarter. The decline reflected weaker domestic laboratory construction demand, with Lab Products Group sales down 6.4 percent and international sales down 7.8 percent.

Profitability also weakened. Diluted EPS fell to USD 0.58 from USD 1.04, while net earnings attributable to Kewaunee Scientific declined to USD 1.706 million from USD 3.093 million, a 44.8 percent decrease.

Backlog offers a counterpoint

The order book provided a different signal. PR Newswire reported that backlog stood at USD 169.0 million on July 31, 2026, compared with USD 165.9 million on April 30, 2026. That sequential increase was paired with a year-over-year decline from USD 205.0 million, showing that project conversion and timing remain important for the next quarters.

International operations were another bright spot inside the quarter. International segment net earnings rose 23.5 percent to USD 794,000, while segment EBITDA increased 13.9 percent to USD 1.202 million, supported by a higher-margin project mix. Consolidated EBITDA, however, declined to USD 4.525 million from USD 6.320 million.

Hold consensus meets thin coverage

MarketBeat lists a Hold consensus for Kewaunee Scientific based on one analyst report in the past 90 days. Its page also shows no published consensus price target, leaving the earnings trend and backlog conversion as the clearest measurable checkpoints.

The company’s balance sheet adds a mixed operating backdrop. As of July 31, 2026, cash on hand was USD 10.261 million, while long-term debt excluding the sale-leaseback financing obligation was USD 13.8 million. The company said project award and release timelines remained extended amid geopolitical and economic uncertainty, even as quoting activity stayed active.

Stock remains below yearly high

Kewaunee Scientific stock closed at USD 34.16 on Nasdaq on October 2, 2026, with a 52-week range of USD 32.00 to USD 46.57 and a market capitalization of USD 99.1 million. The closing price was USD 0.25 above the prior close of USD 33.91, while the stock remained USD 12.41 below its 52-week high.